Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 14/20 | 0.98 |
| ▸ | CNR1 | P21554 | 13/20 | 0.98 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.73 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29611496 | 1.00 | CNR2 (0.98) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| SCHEMBL23802259 | 1.00 | CNR2 (0.98) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| Lenabasum SCHEMBL29872156 | 0.99 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| SCHEMBL13035015 | 0.99 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| Lenabasum SCHEMBL7056881 | 0.99 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| Lenabasum SCHEMBL23202520 | 0.99 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| SCHEMBL17414503 | 0.99 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| Lenabasum SCHEMBL29362927 | 0.99 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| Lenabasum SCHEMBL6406468 | 0.99 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| Lenabasum SCHEMBL7056887 | 0.99 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099988-A1 | ANTI-EMETIC USES OF (3R, 4R)-DELTA8-TETRAHYDROCANNABINOL-11-OIC ACIDS | INDEVUS PHARMACEUTICALS, INC. | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099988-A1 | ANTI-EMETIC USES OF (3R, 4R)-DELTA8-TETRAHYDROCANNABINOL-11-OIC ACIDS | CNR1, CNR2, HCRTR2 | CNR2 2/4885CNR1 1/4885GLRA1 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.